@@ -26,7 +26,7 @@ Even after years of work and advances, the major issue faced by industry still l
</div></center><br><br>
We have found that even small mutations as low as 1 base pair can vary the expressions greatly. With our experiments and dry-lab computations, we have determined 5' UTR sequences with expression rates as low as 30% and as high as 200% of the original, native 5' UTRs. We feel using modified recombinant E. coli can lead to significantly higher yields and hence impact industrial production of therapeutic drugs greatly thereby reducing costs of drugs amongst other benefits.
</p><p>
Our implementation plan involves developing a library for the Dh5α strain of E. coli. We also aim at testing it out in the BL21 strain of the same organism, and making modifications based on our experimentally validated data, the neural network developed by us as well as the data generated by pre-existing software tools. We wish to work on conditional expression as well and modify our UTRs accordingly as suggested by <ahref="{{ url_for('pages', page='human-practices2') }}">Amanda Hughes</a>. This would be a constant iterative process, supplemented by feedback from industrialists and researchers. We would simultaneously be re-evaluating safety features of our organisms if the need arises, look into intellectual property rights to protect our findings, and seek out funding options to increase our scope of operations. Our basic library of parts would be open-source.
Our implementation plan involves developing a library for the Dh5α and BL21(DE3) strains of E. coli. We also aim at testing it out in the MG1655 strain of the same organism, and making modifications based on our experimentally validated data, the neural network developed by us as well as the data generated by pre-existing software tools. We wish to work on conditional expression as well and modify our UTRs accordingly as suggested by Amanda Hughes. This would be a constant iterative process, supplemented by feedback from industrialists and researchers. We would simultaneously be re-evaluating safety features of our organisms if the need arises, look into intellectual property rights to protect our findings, and seek out funding options to increase our scope of operations. Our basic library of parts would be open-source.
</p><p>
As implicated by our literature search, the region downstream of the coding sequence does play a role in the effect of translation initiation but eventually we would be adding a cleavage site there in our basic library. Then, we would also be involving ourselves in projects with industries and providing them with a special custom library for their gene of interest which would be maintained as a trade secret (In this case no changes to the CDS would be made). We would be performing scale up experiments on both a laboratory level and an industrial level. There is a concern on the performance of the cells and UTRs once the volume of the reactor changes. We would be recording these differences, making attempts to understand them better, and ideally make our optimization strategies further enhanced. In cases where a cleavage site is added to standardise the 5' UTRs, characterisation of the protein would be required again.
